晚期甲状腺髓样癌患者循环RET M918T突变肿瘤DNA的预后意义
本研究通过微滴式数字PCR检测晚期甲状腺髓样癌(MTC)患者血浆中携带RET M918T突变的游离DNA(cfDNA),纳入75例散发性MTC患者,其中50例组织活检证实存在RET M918T突变。在组织活检阳性的50例患者中,16例(32%)检出RET M918T cfDNA,其检出与更差的总生存期强烈相关,且比降钙素倍增时间更准确地预测不良结局。结论认为液体活检检测RET M918T突变特异性高但敏感性低,在已确定体细胞RET M918T突变的患者中,循环肿瘤DNA的等位基因分数对总生存期有预后价值,可能有助于监测治疗反应。
要点
- 在组织活检证实RET M918T突变的50例晚期MTC患者中,16例(32%)血浆中检出RET M918T cfDNA。
- RET M918T cfDNA检出与更差的总生存期强烈相关,且比降钙素倍增时间更准确预测不良结局。
- 液体活检检测RET M918T突变特异性高但敏感性低,循环肿瘤DNA等位基因分数对总生存期有预后价值。
核心结论
- 液体活检能够以高特异性但低敏感性检测患者血浆中的RET M918T突变。
- 在已确定体细胞RET M918T突变的患者中,循环肿瘤DNA的等位基因分数对总生存期有预后价值,并可能有助于监测治疗反应。
研究设计与样本
- 研究通过微滴式数字PCR检测MTC患者血浆中携带RET M918T突变的cfDNA水平。
- 纳入75例确诊散发性MTC患者,血清降钙素>100 pg/mL,且肿瘤组织活检提供RET M918T突变状态,其中50例组织活检存在RET M918T突变。
主要发现
- 在组织活检阳性的50例患者中,16例(32%)检出RET M918T cfDNA。
- RET M918T cfDNA的检出与更差的总生存期强烈相关,且比降钙素倍增时间更准确地预测不良结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Interpretation of calcitonin measurement to predict the prognosis of medullary thyroid carcinoma (MTC) requires multiple measurements over an extended time period, making it an imperfect biomarker for evaluating prognosis or disease behavior. Single circulating cell-free DNA (cfDNA) values have been shown to be a valuable prognostic marker for several solid tumors. OBJECTIVE: We tested the hypothesis that cfDNA containing the RET M918T mutation could be detected in the blood of patients with advanced MTC whose tumor harbored an M918T mutation and would be able to predict overall survival more reliably than calcitonin. DESIGN: The level of cfDNA containing RET M918T mutation was measured in the plasma of patients with MTC via droplet digital polymerase chain reaction. PATIENTS: Patients had a confirmed sporadic MTC diagnosis, a serum calcitonin measurement >100 pg/mL, and tumor tissue biopsy results providing RET M918T mutation status. There were 75 patients included in this study, 50 of whom harbored an RET M918T mutation by tissue biopsy. RESULTS: RET M918T cfDNA was detected in 16 of 50 patients (32%) with a positive tissue biopsy. The detection of RET M918T cfDNA strongly correlated with worse overall survival and more accurately predicted a worse outcome than calcitonin doubling time. CONCLUSIONS: Liquid biopsy is able to detect RET M918T mutations in patient plasma with high specificity but low sensitivity. In patients with established somatic RET M918T mutations, the allelic fraction of circulating tumor DNA is prognostic for overall survival and may play a role in monitoring response to treatment.
引用
- Cote GJ, Evers C, Hu MI, et al. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017. PMID: 28911154. doi:10.1210/jc.2017-01039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。